His remarks underscored the need to strengthen India's capabilities in drug development, biosimilars and pharmaceutical innovation
The launch builds on the established performance of the PanOptix platform
Achieved global milestone with mass graphology campaign for Indian medical fraternity
Rocket is advancing toward important milestones across its cardiovascular pipeline
Cognizant will bring its life sciences and technology expertise to Gilead’s development and operations environment
The facility offers customers an integrated route from early discovery to process development and multi-kilogram cGMP manufacturing
The deal will also broaden Ofichem’s scientific capabilities, adding expertise in polysaccharides, small peptides and complex new chemical entities
The consolidation is expected to give patients across Mumbai and Maharashtra access to a broader range of routine and highly specialised diagnostic services
The Consortium is combining existing industry guidelines with new standards designed to address gaps that have slowed digital adoption
Biodegradable polymer platform builds on Evonik’s seven-decade track record in oral drug delivery
Endowment will fund academic leadership in dermatology in perpetuity, supporting research, education and mentorship
MSN Laboratories developed, manufactured, and received US Food and Drug Administration (FDA) approval for a generic equivalent to Adempas tablets in all five strengths
The deal replaces the greenfield R&D centre that Sai Parenterals had originally planned to build using funds earmarked in its IPO objects
Healthcare M&A activity totalled Rs. 19 billion during the month, with three major deals recorded
The companies are advancing ivonescimab in combination with antibody-drug conjugates (ADCs) across multiple tumour types
Procedures surge close to five-fold: Experts
Lupin Formoflo-G is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD
The Differin Gel, 0.1% (OTC) market achieved annual sales of approximately $45.8 million
NICE’s recommendation is supported by positive results from the Phase 3 Balance study
Subscribe To Our Newsletter & Stay Updated
